Trial Profile
An open-label, parallel multicenter study of use of remdesivir in patients with varying degrees of chronic renal impairment
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2022
Price :
$35
*
At a glance
- Drugs Remdesivir (Primary)
- Indications COVID 2019 infections; COVID-19 pneumonia; Ebola virus infections; Neurological disorders
- Focus Adverse reactions; Pharmacokinetics
- 08 Nov 2022 New trial record
- 27 Sep 2022 Results presented at the 2022 American College of Clinical Pharmacology Annual Meeting